AstraZeneca to acquire Gracell Biotechnologies for $1.2bn to expand cell therapy capabilities
AstraZeneca has announced a definitive agreement to acquire Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL) for an upfront cash payment of $1.0 billion, representing a 62% ... Read More
Absci collaborates with AstraZeneca for AI-designed oncology antibody
Absci Corporation (Nasdaq: ABSI), a leader in generative AI antibody discovery, announced a groundbreaking collaboration with AstraZeneca, a global biopharmaceutical company. This partnership aims to ... Read More
AbbVie to acquire ImmunoGen for $10.1bn to expand oncology portfolio
AbbVie Inc. and ImmunoGen Inc. have entered into a definitive agreement, marking a significant move in the pharmaceutical industry. AbbVie will acquire ImmunoGen, including its ... Read More
Perpetual Medicines secures $8m for peptide drug discovery platform
Perpetual Medicines, a frontrunner in computational peptide therapeutics, recently announced an impressive $8 million seed financing round, spearheaded by Chengwei Capital. This significant financial injection ... Read More
GSK’s DREAMM-7 trial shows promising results for Blenrep in multiple myeloma
GSK plc has unveiled positive outcomes from the DREAMM-7 head-to-head phase III trial, evaluating Blenrep (belantamab mafodotin) as a treatment for relapsed or refractory multiple ... Read More
Curium wraps up patient enrollment in ECLIPSE trial in prostate cancer
Curium, a leading figure in the global nuclear medicine sector, has proudly announced the successful completion of patient enrollment in the pivotal Phase 3 ECLIPSE ... Read More
Boehringer Ingelheim expands oncology portfolio with T3 Pharma acquisition
Boehringer Ingelheim announced its acquisition of T3 Pharmaceuticals AG (“T3 Pharma”), a Swiss biotech company specializing in immuno-oncology, for up to 450 million CHF. T3 ... Read More
FDA approves AstraZeneca’s Truqap for advanced breast cancer treatment
In a notable development in the field of oncology, the US Food and Drug Administration (FDA) has approved AstraZeneca’s Truqap (capivasertib) in combination with Faslodex ... Read More
ValiRx and StingRay Bio collaborate on preclinical cancer therapeutics research
ValiRx Plc (AIM: VAL), a pioneering life science company, has entered into a strategic agreement with StingRay Bio Limited to evaluate a series of drug ... Read More
Crown Bioscience launches OrganoidXplore: A game-changer for preclinical oncology research
Leading global contract research organization, Crown Bioscience, has unveiled OrganoidXplore, a trailblazing service offering in the domain of preclinical oncology research. This state-of-the-art platform promises ... Read More